{"pmid":32367812,"title":"[First case of COVID-19 treated with tocilizumab in Iceland].","text":["[First case of COVID-19 treated with tocilizumab in Iceland].","A gentleman in his early fifties became ill with flu-like symptoms after vacationing abroad and was diagnosed with COVID-19 after returning to Iceland. A few days later he was admitted to the University Hospital, Landspitali, due to worsening respiratory symptoms and severe fatigue. A computed tomography scan of lthe lungs showed diffuse bilateral consolidations and ground glass changes. He developed respiratory failure and was transferred to the intensive care unit where he received further treatment, including tocilizumab (IL-6 receptor inhibitor). He subsequently showed clinical improvement and did not require endotracheal intubation.","Laeknabladid","Bjornsson, Aron Hjalti","Olafsdottir, Thorbjorg","Thormar, Katrin Maria","Kristjansson, Mar","Thorisdottir, Anna Sesselja","Ludviksson, Bjorn Runar","Guethmundsson, Sigurdur","Gottfredsson, Magnus","32367812"],"abstract":["A gentleman in his early fifties became ill with flu-like symptoms after vacationing abroad and was diagnosed with COVID-19 after returning to Iceland. A few days later he was admitted to the University Hospital, Landspitali, due to worsening respiratory symptoms and severe fatigue. A computed tomography scan of lthe lungs showed diffuse bilateral consolidations and ground glass changes. He developed respiratory failure and was transferred to the intensive care unit where he received further treatment, including tocilizumab (IL-6 receptor inhibitor). He subsequently showed clinical improvement and did not require endotracheal intubation."],"journal":"Laeknabladid","authors":["Bjornsson, Aron Hjalti","Olafsdottir, Thorbjorg","Thormar, Katrin Maria","Kristjansson, Mar","Thorisdottir, Anna Sesselja","Ludviksson, Bjorn Runar","Guethmundsson, Sigurdur","Gottfredsson, Magnus"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32367812","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.17992/lbl.2020.05.581","keywords":["covid-19","coronavirus","cytokine storm","sars-cov-2","tocilizumab"],"locations":["Iceland","Landspitali","Iceland"],"countries":["Iceland"],"countries_codes":["ISL|Iceland"],"e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138496239140864,"score":9.490897,"similar":[{"pmid":32350134,"title":"Effective treatment of severe COVID-19 patients with tocilizumab.","text":["Effective treatment of severe COVID-19 patients with tocilizumab.","After analyzing the immune characteristics of patients with severe coronavirus disease 2019 (COVID-19), we have identified that pathogenic T cells and inflammatory monocytes with large amount of interleukin 6 secreting may incite the inflammatory storm, which may potentially be curbed through monoclonal antibody that targets the IL-6 pathways. Here, we aimed to assess the efficacy of tocilizumab in severe patients with COVID-19 and seek a therapeutic strategy. The patients diagnosed as severe or critical COVID-19 in The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) and Anhui Fuyang Second People's Hospital were given tocilizumab in addition to routine therapy between 5 and 14 February 2020. The changes of clinical manifestations, computerized tomography (CT) scan image, and laboratory examinations were retrospectively analyzed. Fever returned to normal on the first day, and other symptoms improved remarkably within a few days. Within 5 d after tocilizumab, 15 of the 20 patients (75.0%) had lowered their oxygen intake, and 1 patient needed no oxygen therapy. CT scans manifested that the lung lesion opacity absorbed in 19 patients (90.5%). The percentage of lymphocytes in peripheral blood, which decreased in 85.0% of patients (17/20) before treatment (mean, 15.52 +/- 8.89%), returned to normal in 52.6% of patients (10/19) on the fifth day after treatment. Abnormally elevated C-reactive protein decreased significantly in 84.2% of patients (16/19). No obvious adverse reactions were observed. All patients have been discharged on average 15.1 d after giving tocilizumab. Preliminary data show that tocilizumab, which improved the clinical outcome immediately in severe and critical COVID-19 patients, is an effective treatment to reduce mortality.","Proc Natl Acad Sci U S A","Xu, Xiaoling","Han, Mingfeng","Li, Tiantian","Sun, Wei","Wang, Dongsheng","Fu, Binqing","Zhou, Yonggang","Zheng, Xiaohu","Yang, Yun","Li, Xiuyong","Zhang, Xiaohua","Pan, Aijun","Wei, Haiming","32350134"],"abstract":["After analyzing the immune characteristics of patients with severe coronavirus disease 2019 (COVID-19), we have identified that pathogenic T cells and inflammatory monocytes with large amount of interleukin 6 secreting may incite the inflammatory storm, which may potentially be curbed through monoclonal antibody that targets the IL-6 pathways. Here, we aimed to assess the efficacy of tocilizumab in severe patients with COVID-19 and seek a therapeutic strategy. The patients diagnosed as severe or critical COVID-19 in The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) and Anhui Fuyang Second People's Hospital were given tocilizumab in addition to routine therapy between 5 and 14 February 2020. The changes of clinical manifestations, computerized tomography (CT) scan image, and laboratory examinations were retrospectively analyzed. Fever returned to normal on the first day, and other symptoms improved remarkably within a few days. Within 5 d after tocilizumab, 15 of the 20 patients (75.0%) had lowered their oxygen intake, and 1 patient needed no oxygen therapy. CT scans manifested that the lung lesion opacity absorbed in 19 patients (90.5%). The percentage of lymphocytes in peripheral blood, which decreased in 85.0% of patients (17/20) before treatment (mean, 15.52 +/- 8.89%), returned to normal in 52.6% of patients (10/19) on the fifth day after treatment. Abnormally elevated C-reactive protein decreased significantly in 84.2% of patients (16/19). No obvious adverse reactions were observed. All patients have been discharged on average 15.1 d after giving tocilizumab. Preliminary data show that tocilizumab, which improved the clinical outcome immediately in severe and critical COVID-19 patients, is an effective treatment to reduce mortality."],"journal":"Proc Natl Acad Sci U S A","authors":["Xu, Xiaoling","Han, Mingfeng","Li, Tiantian","Sun, Wei","Wang, Dongsheng","Fu, Binqing","Zhou, Yonggang","Zheng, Xiaohu","Yang, Yun","Li, Xiuyong","Zhang, Xiaohua","Pan, Aijun","Wei, Haiming"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350134","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1073/pnas.2005615117","keywords":["covid-19","sars-cov-2","cytokine storm","interleukin-6","tocilizumab"],"link_comment_in":"32278585","e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1666138495683395586,"score":217.97527},{"pmid":32437706,"title":"Evolution of SARS-Co-2 RNA test results in a fatal Covid-19 patient: a case report.","text":["Evolution of SARS-Co-2 RNA test results in a fatal Covid-19 patient: a case report.","A 65 year-old man was hospitalized due to fever (38.6 degrees C) and dry cough since 4 days. He visited Wuhan 8 days ago. At admission, nasopharyngeal swabs sample were taken and PCR analysis confirmed SARS-CoV-2RNA positivity. On day 9 after admission, chest CT scan showed diffuse ground-glass shadows in patient's bilateral lungs. On day 11, his respiratory symptoms worsened. Subsequently, type 1 respiratory failure was diagnosed, coinciding with kidney injury, and subsequently, type 2 respiratory failure occurred, coupled with multi-organ failure including heart and liver. However, patient constitution worsened although SARS-CoV-2 tests were negative since day 13. He died on day 21. Lung biopsy showed areas of diffuse alveolar damage, characterized by extensive acute alveolitis with numerous intra-alveolar neutrophils, lymphocytes and macrophages infiltrations. Microthrombi were seen in the dilated pulmonary capillaries. Immunohistochemistry stainings for SARS-CoV-2-N protein was negative. Taken together, the patient died of multiorgan failure although the SARS-CoV-2 infection was cleared already, implicating that for disease worsening, no active SARS-CoV-2 infection is required.","Hum Pathol","Shao, Chen","Liu, Hui","Meng, Lingjia","Sun, Lin","Wang, Yankun","Yue, Zhujun","Kong, Heli","Li, Hongjun","Weng, Honglei","Lv, Fudong","Jin, Ronghua","32437706"],"abstract":["A 65 year-old man was hospitalized due to fever (38.6 degrees C) and dry cough since 4 days. He visited Wuhan 8 days ago. At admission, nasopharyngeal swabs sample were taken and PCR analysis confirmed SARS-CoV-2RNA positivity. On day 9 after admission, chest CT scan showed diffuse ground-glass shadows in patient's bilateral lungs. On day 11, his respiratory symptoms worsened. Subsequently, type 1 respiratory failure was diagnosed, coinciding with kidney injury, and subsequently, type 2 respiratory failure occurred, coupled with multi-organ failure including heart and liver. However, patient constitution worsened although SARS-CoV-2 tests were negative since day 13. He died on day 21. Lung biopsy showed areas of diffuse alveolar damage, characterized by extensive acute alveolitis with numerous intra-alveolar neutrophils, lymphocytes and macrophages infiltrations. Microthrombi were seen in the dilated pulmonary capillaries. Immunohistochemistry stainings for SARS-CoV-2-N protein was negative. Taken together, the patient died of multiorgan failure although the SARS-CoV-2 infection was cleared already, implicating that for disease worsening, no active SARS-CoV-2 infection is required."],"journal":"Hum Pathol","authors":["Shao, Chen","Liu, Hui","Meng, Lingjia","Sun, Lin","Wang, Yankun","Yue, Zhujun","Kong, Heli","Li, Hongjun","Weng, Honglei","Lv, Fudong","Jin, Ronghua"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437706","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.humpath.2020.04.015","keywords":["corona virus","sars-cov-2","multi-organ failure","secondary bacterial infection"],"locations":["Wuhan","multiorgan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1667521393687789568,"score":182.84933},{"pmid":32405160,"pmcid":"PMC7219361","title":"Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.","text":["Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.","Background: Pneumonia with respiratory failure represents the main cause of death in COVID-19, where hyper inflammation plays an important role in lung damage. This study aims to evaluate if tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, reduces patients' mortality. Methods: 85 consecutive patients admitted to the Montichiari Hospital (Italy) with COVID-19 related pneumonia and respiratory failure, not needing mechanical ventilation, were included if satisfying at least one among: respiratory rate >/= 30 breaths/min, peripheral capillary oxygen saturation </= 93% or PaO2/FiO2<=300 mmHg. Patients admitted before March 13th (n=23) were prescribed the standard therapy (hydroxychloroquine, lopinavir and ritonavir) and were considered controls. On March 13th tocilizumab was available and patients admitted thereafter (n=62) received tocilizumab once within 4 days from admission, plus the standard care. Results: Patients receiving tocilizumab showed significantly greater survival rate as compared to control patients (hazard ratio for death, 0.035; 95% confidence interval [CI], 0.004 to 0.347; p = 0.004), adjusting for baseline clinical characteristics. Two out of 62 patients of the tocilizumab group and 11 out of 23 in the control group died. 92% and 42.1% of the discharged patients in the tocilizumab and control group respectively, recovered. The respiratory function resulted improved in 64.8% of the observations in tocilizumab patients who were still hospitalized, whereas 100% of controls worsened and needed mechanical ventilation. No infections were reported. Conclusions: Tocilizumab results to have a positive impact if used early during Covid-19 pneumonia with severe respiratory syndrome in terms of increased survival and favorable clinical course.","Eur J Intern Med","Capra, Ruggero","De Rossi, Nicola","Mattioli, Flavia","Romanelli, Giuseppe","Scarpazza, Cristina","Sormani, Maria Pia","Cossi, Stefania","32405160"],"abstract":["Background: Pneumonia with respiratory failure represents the main cause of death in COVID-19, where hyper inflammation plays an important role in lung damage. This study aims to evaluate if tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, reduces patients' mortality. Methods: 85 consecutive patients admitted to the Montichiari Hospital (Italy) with COVID-19 related pneumonia and respiratory failure, not needing mechanical ventilation, were included if satisfying at least one among: respiratory rate >/= 30 breaths/min, peripheral capillary oxygen saturation </= 93% or PaO2/FiO2<=300 mmHg. Patients admitted before March 13th (n=23) were prescribed the standard therapy (hydroxychloroquine, lopinavir and ritonavir) and were considered controls. On March 13th tocilizumab was available and patients admitted thereafter (n=62) received tocilizumab once within 4 days from admission, plus the standard care. Results: Patients receiving tocilizumab showed significantly greater survival rate as compared to control patients (hazard ratio for death, 0.035; 95% confidence interval [CI], 0.004 to 0.347; p = 0.004), adjusting for baseline clinical characteristics. Two out of 62 patients of the tocilizumab group and 11 out of 23 in the control group died. 92% and 42.1% of the discharged patients in the tocilizumab and control group respectively, recovered. The respiratory function resulted improved in 64.8% of the observations in tocilizumab patients who were still hospitalized, whereas 100% of controls worsened and needed mechanical ventilation. No infections were reported. Conclusions: Tocilizumab results to have a positive impact if used early during Covid-19 pneumonia with severe respiratory syndrome in terms of increased survival and favorable clinical course."],"journal":"Eur J Intern Med","authors":["Capra, Ruggero","De Rossi, Nicola","Mattioli, Flavia","Romanelli, Giuseppe","Scarpazza, Cristina","Sormani, Maria Pia","Cossi, Stefania"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405160","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.ejim.2020.05.009","keywords":["covid-19","pneumonia","respiratory failure","retrospective study","sars-cov-2","tocilizumab"],"e_drugs":["Ritonavir","tocilizumab","Hydroxychloroquine","Lopinavir"],"topics":["Treatment"],"weight":1,"_version_":1666802845572136960,"score":173.32259},{"pmid":32384516,"title":"Novel coronavirus 2019 (COVID-19): A case report and review of treatments.","text":["Novel coronavirus 2019 (COVID-19): A case report and review of treatments.","RATIONALE: Novel coronavirus 2019 (COVID-19) also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, non-segmented positive-sense RNA virus belonging to the beta-coronaviridae family. This virus is known to cause severe bilateral pneumonia and acute respiratory distress syndrome (ARDS) which can lead to difficulty breathing requiring mechanical ventilation and intensive care unit management. PATIENT CONCERNS: A 77-year-old female with a history of hypertension and hyperlipidemia who presented as a transfer to our hospital facility with worsening fevers, cough, and respiratory distress. DIAGNOSIS: Chest X-rays revealed bilateral infiltrates worse at the lung bases and CT scan of the chest showed bilateral ground-glass opacities consistent with COVID-19. While our testing revealed a negative COVID-19 result at our institution, the result at a previous hospital returned a positive result. INTERVENTIONS: She was being treated aggressively in the intensive care unit with high dose intravenous ascorbic acid, hydroxychloroquine, and anti-interleukin-6 monoclonal antibody. She also received a loading dose of remdesivir however was unable to complete the course due to organ failure and requirement of vasopressors for hemodynamic stability. OUTCOMES: She remained critically ill and was eventually placed on comfort care as per the family's wishes and passed away. LESSONS: With a rapidly growing death rate and more than 200,000 confirmed cases worldwide, COVID-19 has become a global pandemic and major hit to our healthcare systems. While several companies have already begun vaccine trials and healthcare facilities have been using a wide-range of medications to treat the virus and symptoms, there is not yet an approved medication regimen for COVID-19 infections. The alarming increase in cases per day adds additional pressure to find a cure and decrease the global health burden and mortality rate.","Medicine (Baltimore)","Douedi, Steven","Miskoff, Jeffrey","32384516"],"abstract":["RATIONALE: Novel coronavirus 2019 (COVID-19) also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, non-segmented positive-sense RNA virus belonging to the beta-coronaviridae family. This virus is known to cause severe bilateral pneumonia and acute respiratory distress syndrome (ARDS) which can lead to difficulty breathing requiring mechanical ventilation and intensive care unit management. PATIENT CONCERNS: A 77-year-old female with a history of hypertension and hyperlipidemia who presented as a transfer to our hospital facility with worsening fevers, cough, and respiratory distress. DIAGNOSIS: Chest X-rays revealed bilateral infiltrates worse at the lung bases and CT scan of the chest showed bilateral ground-glass opacities consistent with COVID-19. While our testing revealed a negative COVID-19 result at our institution, the result at a previous hospital returned a positive result. INTERVENTIONS: She was being treated aggressively in the intensive care unit with high dose intravenous ascorbic acid, hydroxychloroquine, and anti-interleukin-6 monoclonal antibody. She also received a loading dose of remdesivir however was unable to complete the course due to organ failure and requirement of vasopressors for hemodynamic stability. OUTCOMES: She remained critically ill and was eventually placed on comfort care as per the family's wishes and passed away. LESSONS: With a rapidly growing death rate and more than 200,000 confirmed cases worldwide, COVID-19 has become a global pandemic and major hit to our healthcare systems. While several companies have already begun vaccine trials and healthcare facilities have been using a wide-range of medications to treat the virus and symptoms, there is not yet an approved medication regimen for COVID-19 infections. The alarming increase in cases per day adds additional pressure to find a cure and decrease the global health burden and mortality rate."],"journal":"Medicine (Baltimore)","authors":["Douedi, Steven","Miskoff, Jeffrey"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32384516","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1097/MD.0000000000020207","topics":["Case Report"],"weight":1,"_version_":1666267276769230848,"score":171.00362},{"pmid":32157862,"pmcid":"PMC7161622","title":"CT Manifestations of Novel Coronavirus Pneumonia: A Case Report","text":["CT Manifestations of Novel Coronavirus Pneumonia: A Case Report","Background: Since December 2019, the outbreak of the novel coronavirus has impacted nearly >90,000 people in more than 75 countries. In this case report, we aim to define the chest computed tomography findings of 2019-novel coronavirus associated with pneumonia and its successful resolution after treatment. Case Report: A fifty-year-old female patient, who is a businesswoman, presented with chief complaints of \"fever for one week, diarrhea, anorexia, and asthenia.\" Initially, she was given Tamiflu. The influenza A virus serology was negative. Three days later, levofloxacin was started because the patient's symptoms did not improve. The novel coronavirus nucleic acid test was negative. It was noted that before the onset of the disease, the patient went to Wuhan on a business trip. Despite the given treatment, her body temperature rose to 39.2 degrees C and she was referred to our clinic for further evaluation. Then, chest computed tomography was performed and showed bilateral multifocal ground glass opacities with consolidation which suggested viral pneumonia as a differential diagnosis, and the subsequent 2019-novel coronavirus pneumonia nucleic acid test was positive. Conclusion: Chest computed tomography offers fast and convenient evaluation of patients with suspected 2019-novel coronavirus pneumonia.","Balkan Med J","An, Peng","Song, Ping","Lian, Kai","Wang, Yong","32157862"],"abstract":["Background: Since December 2019, the outbreak of the novel coronavirus has impacted nearly >90,000 people in more than 75 countries. In this case report, we aim to define the chest computed tomography findings of 2019-novel coronavirus associated with pneumonia and its successful resolution after treatment. Case Report: A fifty-year-old female patient, who is a businesswoman, presented with chief complaints of \"fever for one week, diarrhea, anorexia, and asthenia.\" Initially, she was given Tamiflu. The influenza A virus serology was negative. Three days later, levofloxacin was started because the patient's symptoms did not improve. The novel coronavirus nucleic acid test was negative. It was noted that before the onset of the disease, the patient went to Wuhan on a business trip. Despite the given treatment, her body temperature rose to 39.2 degrees C and she was referred to our clinic for further evaluation. Then, chest computed tomography was performed and showed bilateral multifocal ground glass opacities with consolidation which suggested viral pneumonia as a differential diagnosis, and the subsequent 2019-novel coronavirus pneumonia nucleic acid test was positive. Conclusion: Chest computed tomography offers fast and convenient evaluation of patients with suspected 2019-novel coronavirus pneumonia."],"journal":"Balkan Med J","authors":["An, Peng","Song, Ping","Lian, Kai","Wang, Yong"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32157862","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.4274/balkanmedj.galenos.2020.2020.2.15","keywords":["influenza","novel coronavirus pneumonia","pulmonary complications","computed tomography","diagnosis"],"locations":["diarrhea","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Oseltamivir","Levofloxacin"],"topics":["Case Report"],"weight":1,"_version_":1666138492675031040,"score":160.8629}]}